Effects of Sugammadex and Conventional Reversal on Lung Function in Laparoscopic Abdominal Surgery
Launched by RHENDRA HARDY MOHAMAD ZAINI · Jan 6, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how two different medications—Sugammadex and a traditional reversal drug called neostigmine—affect lung function after laparoscopic abdominal surgery, which is a minimally invasive procedure. The researchers want to find out if there are any differences in lung function tests and the size of lung areas that may have collapsed (called atelectasis) between the two groups of patients. They will also see if the type of medication affects how long patients stay in the hospital after surgery.
To participate, you need to be between 18 and 75 years old, have a diagnosis of appendicitis or gallstones, and be scheduled for laparoscopic surgery. Before the operation, you will have some lung tests and an ultrasound. After the surgery, depending on which medication you receive, you will have additional lung tests and ultrasounds to compare the effects. It’s important to know that if you have certain health conditions, such as unstable heart issues or chronic lung diseases, you may not be eligible for this trial.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed / suspected: appendicitis or cholelithiasis
- • Planned for laparoscopic operation under general anaesthesia
- • ASA I-III
- Exclusion Criteria:
- • 1. Unstable haemodynamic status
- • 2. Patient refusal to participate
- • 3. Altered mental status, cognitive function or mental disorder
- • 4. Admission to postoperative care unit (PACU) under mechanical ventilation
- • 5. Hypersensitivity to any of the drugs
- • 6. Acute or chronic lung diseases
- • 7. Neuromuscular disorders
- • 8. Myocardial infarction or coronary occlusion three months prior surgery
- • 9. Obesity BMI more or equal 30
- • 10. Intubation prior operating room arrival
- • 11. Pregnancy
- • 12. Converted to open surgery
About Rhendra Hardy Mohamad Zaini
Rhendra Hardy Mohamad Zaini is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes. With a focus on innovative therapies and methodologies, the organization engages in rigorous clinical studies that adhere to the highest ethical and regulatory standards. Leveraging a team of experienced professionals and a robust network of clinical sites, Rhendra Hardy Mohamad Zaini aims to facilitate the development of safe and effective treatments across various therapeutic areas, ultimately contributing to the enhancement of healthcare practices and patient quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kubang Kerian, Kelantan, Malaysia
Patients applied
Trial Officials
NIK MUHAMMAD 'AIZAT 'ADROS, MBBS
Principal Investigator
Hospital Universiti Sains Malaysia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported